Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Coming of age of personalized medicine: challenges ahead Address: Centre for Biomedical Ethics and Law, Katholieke | Genome Medicine Meeting report Coming of age of personalized medicine challenges ahead Pascal Borry Address Centre for Biomedical Ethics and Law Katholieke Universiteit Leuven Kapucijnenvoer 35 3000 Leuven Belgium. Email Abstract A report on the 5th International DNA Sampling Conference The age of personal genomics Banff Canada 16-18 September 2009. Introduction This 3-day conference brought together scholars involved in the ethical legal and social controversies around the rapidly developing field of personalized genomics. More than 100 leading international experts in law ethics communications studies genomic medicine and research came together for in-depth discussion on key issues such as research ethics and governance challenges the integration of personalized genomics into healthcare media and popular representation of personal genomics commercialization of personalized genomics and the regulation of direct-to-consumer DTC genetic testing. Here I focus on a few topics that were discussed during the conference and that will continue to raise debate in the field of personalized genomics. Genomics and personalized medicine Wylie Burke University of Washington Seattle USA made the distinction between genomics and personalized medicine and personalized genomics . She wanted to stress that personalized healthcare is mostly not about genetics and that the main question is whether and how we can extend the paradigm of personalized medicine to genomics. She said Tailoring care to the individual patient is a central goal of medical practice. As new knowledge and technology develop clinicians and policy makers have the task of considering how and when they can be used to improve the standard of care. Personal genomic testing offers several potential benefits including new strategies for risk assessment improved disease classification and guidance to improve drug safety and efficacy. But such testing poses potential harms as well and is often
